gallbladder carcinoma
Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:4948
Name gallbladder carcinoma
Definition A gallbladder cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells.
Source DiseaseOntology.org
Alt Ids
Xrefs
SNOMEDCT_US_2023_03_01:93810008
Path disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer hepatobiliary system cancer biliary tract cancer gallbladder cancer gallbladder carcinoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
ATM S1905Ifs*25 Olaparib gallbladder carcinoma predicted - sensitive detail...
STK11 K262Sfs*25 Everolimus gallbladder carcinoma no benefit detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01174121 Phase II Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Recruiting USA 0
NCT02042443 Phase II Fluorouracil + Leucovorin Capecitabine Trametinib Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Completed USA 0
NCT02115542 Phase II Regorafenib Single Agent Regorafenib in Refractory Advanced Biliary Cancers Completed USA 0
NCT02151084 Phase II Cisplatin + Gemcitabine + Selumetinib A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer Active, not recruiting CAN 0
NCT02631590 Phase II Cisplatin + Copanlisib + Gemcitabine Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma Completed USA 0
NCT02829918 Phase II Nivolumab Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers Completed USA 0
NCT03260712 Phase II Cisplatin + Gemcitabine + Pembrolizumab Pembrolizumab in Biliary Tract Cancer Completed GBR | ESP | DEU 0
NCT03704480 Phase II Durvalumab + Tremelimumab Durvalumab Plus Tremelimumab Combination Immunotherapy With or Without Weekly Paclitaxel in Patients With Advanced Biliary Tract Carcinoma (BTC) After Failure of Platinum-based Chemotherapy (IMMUNO-BIL) Active, not recruiting FRA 0
NCT04003896 Phase II Abemaciclib A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma Who Failed Prior First Line Therapy Terminated USA 0
NCT04068194 Phase Ib/II Avelumab Avelumab + Peposertib Testing the Combination of New Anti-cancer Drug Nedisertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies Suspended USA 0
NCT04137289 Phase I BI 905711 A First-in-human Phase Ia/b, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Patients With Advanced Gastrointestinal Cancers Completed USA | FRA | ESP | DEU | BEL 3
NCT04203160 Phase Ib/II Cisplatin + Gemcitabine Cisplatin + CPI-613 + Gemcitabine Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) Terminated USA 0
NCT04430738 Phase Ib/II Pembrolizumab + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib Capecitabine + Oxaliplatin + Pembrolizumab + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab + Trastuzumab + Tucatinib Capecitabine + Oxaliplatin + Trastuzumab + Tucatinib Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers Active, not recruiting USA 1
NCT04677504 Phase II Atezolizumab + Cisplatin + Gemcitabine Atezolizumab + Bevacizumab + Cisplatin + Gemcitabine A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer Completed USA | TUR | POL | ITA | GBR | ESP 7
NCT04941287 Phase II Atezolizumab + Varlilumab Atezolizumab + Cobimetinib + Varlilumab Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of A Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer Active, not recruiting USA 0
NCT04969887 Phase II Ipilimumab + Nivolumab Combination Immunotherapy in Rare Cancers Under InvesTigation (MOST-CIRCUIT) Active, not recruiting NZL | AUS 0
NCT05194072 Phase I SGN-B7H4V A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors Terminated USA | GBR | ESP | DEU | CAN 0
NCT05239169 Phase II Capecitabine + Durvalumab + Tremelimumab Durvalumab + Tremelimumab Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer Completed DEU 0
NCT05615818 Phase III Niraparib Zanidatamab Binimetinib + Encorafenib Futibatinib Cisplatin + Gemcitabine Neratinib + Trastuzumab Ivosidenib Personalized Medicine for Advanced Biliary Cancer Patients (SAFIR-ABC10) Recruiting GBR | FRA | BEL 0
NCT05712356 Phase II CEND-1 + Cisplatin + Durvalumab + Gemcitabine Cisplatin + Durvalumab + Gemcitabine Paclitaxel Docetaxel CEND-1 + Docetaxel CEND-1 + Paclitaxel A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors (BOLSTER) Active, not recruiting USA 0
NCT05733598 Phase II Durvalumab + RP2 Atezolizumab + Bevacizumab + RP2 RP2 Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC Recruiting USA 0
NCT06529718 Phase II Fluorouracil + Leucovorin + Oxaliplatin Ivonescimab Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients (SEVILLA) Recruiting GBR | FRA 0
NCT06546969 Phase I Cisplatin + Durvalumab + Gemcitabine Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer Recruiting USA 0
NCT07107750 Phase I CA-4948 + Cisplatin + Durvalumab + Gemcitabine CA-4948 in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer Not yet recruiting USA 0
NCT07146646 Phase II Oxaliplatin + Trifluridine-tipiracil hydrochloride Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer Recruiting USA 0
NCT07221253 Phase III Cisplatin + Durvalumab + Gemcitabine AZD2936 + Cisplatin + Gemcitabine A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) (AB02) Recruiting USA | TUR | POL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS 6
NCT07265674 Phase III Fluorouracil + Irinotecan + Leucovorin JPH203 Fluorouracil + Leucovorin + Oxaliplatin A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer (Beacon-BTC) Recruiting USA 0